In this article
EDGE Radiosurgery System: Advanced Noninvasive Tumor Removal Technology
There are new developments for patients suffering from liver cancer with brain metastasis. The EDGE Radiosurgery system (EDGE radiosurgery system) was developed by the American Varian company and was approved by the US FDA on January 23, 2013. It is by far the most effective noninvasive tumor removal technology, which can dynamically monitor and lock the treatment in real time During the process, the tumor “escapes”, and the high-intensity, precise rays remove the tumor tissue almost without leaving a residue.
Speed blade system
The world’s first speed-blade system was settled in the United States of America Henry Ford Medical Group in September 2013, and in Italy Humanitas Research Hospital in February 2014. The Global Oncologist Network has successively signed cooperation agreements with these two hospitals for international cancer patients.
Advantages of speed blade
High strength and precision, completely remove tumor tissue, almost no residue
Almost no effect on surrounding normal tissues, important organs and autoimmune system
Track and lock “escape” tumor cells in real time and clear them
Improve patient compliance, treatment process is comfortable and painless
Treatment time is short, 8 to 20 minutes per day for a total of 1 to 5 days
Low cost: The cost of treatment in the United States is about 400,000, while that in Italy is only about 100,000.
Case Study
Patient male, 65 years old. In October 2014, the patient felt abdominal discomfort and headache. The examination and diagnosis results were (1) well-differentiated hepatocellular carcinoma, approximately 10 cm in size, with significant cirrhosis. (2) Brain metastases with a mass of about 3 cm in the left occipital lobe. (3) Type II diabetes requires insulin therapy. (4) Chronic kidney disease; (5) Moderate hypertension with a history of heart failure.
The patient is in the advanced stage of liver cancer, the liver cancer is huge and has brain metastases, and domestic medical institutions cannot perform surgical treatment. The Global Oncologist Network invited the international cancer expert team to conduct a remote consultation. The patient is scheduled to undergo EDGE non-invasive surgical treatment on November 10, 2014. He performed EDGE treatment on liver tumors and brain metastases, and treated them in the hospital for 8 days. Each tumor is treated once a day, each treatment time is about 10 minutes, liver tumors are treated 6 times, and brain tumors are treated 4 times. The patient had no discomfort during the operation and returned to the apartment to rest after each treatment. Six months later, the patient was in good health and his weight increased significantly. The imaging report showed that the huge tumor of the liver was completely cleared, and the brain tumor was almost completely eliminated without recurrence. The results of biochemical examination showed no abnormal liver function.
Humanitas Research Hospital and Advantages of Cancer Treatment in Italy
Humanitas Research Hospital in Milan, Italy is the flagship hospital of Humanitas Enterprise Group. It is a highly specialized hospital, research center and teaching center. It has been recognized by the National Health and Medical System and has the mission of providing outstanding and highly specialized diagnosis and treatment services to the majority of patients. Humanitas Hospital is considered to be one of the most technologically advanced hospitals in Europe, equipped with a generation of technology. It is currently one of the three hospitals in the world that can provide the most advanced stereotactic radiotherapy (SBRT)-EDGE treatment.
The hospital has established a cancer center, a cardiovascular center, a neurological disease center and an orthopedic disease prevention and treatment center-in addition to an ophthalmology center and a reproductive medicine center.
According to the World Health Organization, Italy has ranked first in the world in medical standards for many years in a row and is the world leader in cancer treatment. Due to Italy’s perfect and superior medical security system, the cost of medical treatment is very low, and the cost of patients going to Italy for treatment with Sufeng knife is about RMB 100,000, which is only 1/4 of that in the United States. In addition, the Italian visa is simple and only takes twelve hours to arrive in Milan. Italy has a pleasant climate, beautiful scenery, and friendly and enthusiastic people.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.